All Episodes
|
63
|
John Marchica

Episode 63: Our Take, July 29, 2019

Jul 29, 2019

Episode Summary

In today’s Our Take read-in, we discuss a bipartisan bill to lower drug prices that cleared a Senate committee. On Thursday, the Senate Finance Committee voted 19-9 to advance a bill proposed by Sens. Chuck Grassley, R-Iowa, and Ron Wyden, D-Ore., that includes numerous provisions to lower drug prices. The bill, called the Prescription Drug Pricing Reduction Act (PDPRA) of 2019, is likely to undergo considerable changes before it reaches the Senate floor for a full vote — if it gets that far.

Episode Notes

In today’s Our Take read-in, we discuss a bipartisan bill to lower drug prices that cleared a Senate committee. On Thursday, the Senate Finance Committee voted 19-9 to advance a bill proposed by Sens. Chuck Grassley, R-Iowa, and Ron Wyden, D-Ore., that includes numerous provisions to lower drug prices. The bill, called the Prescription Drug Pricing Reduction Act (PDPRA) of 2019, is likely to undergo considerable changes before it reaches the Senate floor for a full vote — if it gets that far.

Over the span of a decade, the PDPRA as it currently stands would save $85 billion in Medicare spending and another $15 billion in Medicaid spending. Further, the Congressional Budget Office estimated that Medicare beneficiaries would save $27 billion in out-of-pocket costs and $5 billion in premiums during that same time period.

Other briefs include:

  • New research on ACOs with two-sided risk suggests lower costs and improved health outcomes.
  • Tenet Healthcare Corp. is spinning off its Conifer business unit.
  • CVS is testing a coordinated care pilot for Aetna beneficiaries requiring knee replacements.
  • Civica Rx signs a five-year agreement with London-based Hikma, a generic drug manufacturer.
  • Advocate Aurora Health names former Advocate CEO Jim Skogsbergh as president and CEO.
  • Paula Steiner leaves her post as CEO of Health Care Services Corp.
  • CVS Health names Dr. Sree Chaguturu as chief medical officer for CVS Caremark.
  • Dr. Reshma Kewalramani is being elevated to CEO of Vertex Pharmaceuticals.

About Darwin Research Group
Darwin Research Group Inc. provides advanced market intelligence and in-depth customer insights to health care executives, with a strategic focus on health care delivery systems and the global shift toward value-based care. Darwin’s client list includes forward-thinking biopharmaceutical and medical device companies, as well as health care providers, private equity, and venture capital firms. The company was founded in 2010 as Darwin Advisory Partners, LLC and is headquartered in Scottsdale, Ariz. with a satellite office in Princeton, N.J.

CONNECT WITH US:

🌐 Visit us on the web

🌐 Follow Health Care Rounds on LinkedIn

🌐 Follow Darwin Research Group on LinkedIn

📺 Watch Health Care Rounds on YouTube

🎧 Listen on Apple Podcasts

🎧 Listen on Spotify

⚙️ Health Care Rounds is produced by Grippi Media

Recommended Next

Podcast 200: How Health Systems Build Elite Clinical Leaders w/ Dr. Jonathan Stallkamp, CMO, Main Line Health
Podcast 199: A New Blueprint for Rural Health Care w/ Natalie L. Baggio, President, Corewell Health South
Podcast 198: Standing Strong as an Independent Health System w/ Dr. Allen Smith & Dr. Sam Ash, South Shore Health
Podcast 197: Making Health Care Costs Simple and Transparent w/ Mark Cuban, Co-Founder, Cost Plus Drugs
Podcast 196: Physician Leadership in a New Era of Health Care w/ Dr. Sowmya Viswanathan, Baycare
Podcast 195: Why Primary Care Is Under Strain w/ Dr. Greg Whisman, Chief Medical Officer, CareMore Health
Podcast 194: Why Health Care Reform Keeps Failing w/ Dr. David Shulkin
Podcast 193: The New Model for Specialty Pharmacy w/ Jigar Thakkar, PharmD

Recommended Content

Browse Library
INsights
February 16, 2026

Darwin's Our Take: Feature: A rare FDA refusal, CDC grant cuts, and proposed ACA exchange changes

Read More
INsights
February 9, 2026

Darwin's Our Take: Lilly’s, Novo Nordisk’s share prices roller-coaster following earnings reports

Read More
INsights
February 2, 2026

Darwin's Our Take: Botox, Trulicity, Xolair among drugs selected for next round of Medicare price negotiations

Read More
Stay Aware. Stay Informed.

Subscribe to Our Take

Sign up for Our Take Newsletter: highly curated, expert weekly strategic insights for health care executives.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.